MAP2K7 and melanoma: Through the screening of pharmacological inhibitors, researchers have identified how to selectively target a resistant subpopulation of melanoma by combining birinapant, an inhibitor of cellular inhibitor of apoptosis 1/2 (cIAP1/2), with Braf/Mek inhibitors.